Hospitals | April 04, 2026
Kauvery Hospital sets new benchmark in high-risk cardiac care
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Subscribe To Our Newsletter & Stay Updated
